Abstract
Single-photon emission computerized tomography (SPECT) in combination with computerized tomography (CT) allows integration of functional and anatomic information, and SPECT-CT is playing an increasingly important role in imaging of differentiated thyroid cancer. This chapter reviews the relevant literature supporting the utility of radioiodine SPECT-CT and its impact on management of patients with differentiated thyroid cancer. Selected images demonstrating the utility of SPECT-CT are presented.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Spies WJ, Wojtowicz CH, Spies SM, et al. Value of post-therapy whole body 131I imaging in the evaluation of patients with thyroid carcinoma having undergone high-dose 131I therapy. Clin Nucl Med. 1989;14:892–00.
Simpson WJ, Panzarella T, Carruthers JS, et al. Papillary and follicular thyroid cancer: impact of treatment in 1578 patients. Int J Radiat Oncol Biol Phys. 1998;14:1063–75.
van Sorge-van Boxtel RA, van Eck-Smit BL, Goslings BM. Comparison of serum thyroglobulin, 131I and 201Tl scintigraphy in the prospective follow-up of differentiated thyroid cancer. Nucl Med Commun. 1993;14:365–72.
Lubin E, Mechlis-Frisch S, Zatz S, et al. Serum thyroglobulin and iodine-131 whole body scan in the diagnosis and assessment of treatment for metastatic differentiated thyroid carcinoma. J Nucl Med. 1994;35:257–62.
Sutter CW, Masilungan B, Stadalnik RC. False-positive results of 131I whole body scans in patients with thyroid cancer. Semin Nucl Med. 1995;25:279–82.
Franceschi M, Kusic Z, Franceschi D, et al. Thyroglobulin determination, neck ultrasonography and iodine-131 whole-body scintigraphy in differentiated thyroid carcinoma. J Nucl Med. 1996;37:446–51.
Filesi M, Signore A, Ventroni G, et al. Role of initial iodine-131whole-body scan and serum thyroglobulin in differentiated thyroid carcinoma metastases. J Nucl Med. 1998;39:1542–6.
Lind P, Kohlufurest S. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in assessment of thyroid cancer. Semin Nucl Med. 2006;36:194–205.
Lang T, Hasagawa B, Liew S, et al. Description of a prototype emission-transmission computed tomography imaging system. J Nucl Med. 1992;33:1881–7.
The 2007 Recommendations of the International Commission on Radiological Protection, ICRP publication 103. Ann ICRP. 2007;37:1–332.
Mettler F, Huda W, Yoshizumi TT, et al. Effective doses in radiology and diagnostic nuclear medicine: a catalog. Radiology. 2008;248:254–63.
MIRD Dose Estimate Report No. 5 (data gathered in human subjects). J Nucl Med 1975;16:857–60 (25% thyroid uptake).
Wong KK, Zarzhevsky N, Cahill JM, Frey KA, Avram AM. Incremental value of diagnostic 131I SPECT-CT fusion imaging in the evaluation of differentiated thyroid carcinoma. Nucl Med Mol Imaging. 2008;191:1785–94.
Chen L, Luo Q, Shen Y, et al. Incremental value of 131I SPECT-CT in the management of patients with differentiated thyroid carcinoma. J Nucl Med. 2008;49:1952–7.
Wong KK, Sisson JC, Koral KF, et al. Staging of differentiated thyroid carcinoma using diagnostic 131I SPECT/CT. Nucl Med Mol Imaging. 2010;195:730–6.
Aide N, Heutte N, Rame JP, et al. Clinical relevance of SPECT-CT of the neck and thorax in postablation 131I scintigraphy for thyroid cancer. J Clin Endocrinol Metab. 2009;94:2075–84.
Schmidt D, Szikszai A, Linke R, Bautz W, et al. Impact of 131I SPECT-spiral CT on nodal staging of differentiated thyroid carcinoma at the first radioablation. J Nucl Med. 2009;50:18–23.
Ruf J, Lehmkuhl L, Bertram H, et al. Impact of SPECT and integrated low-dose CT after radioiodine therapy on the management of patients with thyroid carcinoma. Nucl Med Commun. 2004;25:1177–82.
Tharp K, Israel O, Hausmann J, et al. Impact of 131I-SPECT/CT images obtained with an integrated system in the follow-up of patients with thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2004;31:1435–42.
Kohlfuerst S, Igerc I, Lobnig M, et al. Post-therapeutic 131I SPECT-CT offers high diagnostic accuracy when the findings on conventional planar imaging are inconclusive and allows a tailored patient treatment regimen. Eur J Nucl Med Mol Imaging. 2009;36:886–93.
Mustafa M, Kuwert T, Weber K, et al. Regional lymph node involvement in T1 papillary thyroid carcinoma: a bicentric prospective SPECT/CT study. Eur J Nucl Med Mol Imaging. 2010;37:1462–6.
Spanu A, Solinas ME, Chessa, et al. 131I SPECT/CT in the follow-up of differentiated thyroid carcinoma: incremental value versus planar imaging. J Nucl Med. 2009;50:184–90.
Sgouros G, Frey E, Wahl R, et al. Three dimensional imaging-based radiobiological dosimetry. Semin Nucl Med. 2008;38:321–34.
Prideaux AR, Song H, Hobbs RF, et al. Three-dimensional radiobiologic dosimetry: application of radiobiologic modeling to patient-specific-3dimensional imaging-based internal dosimetry. J Nucl Med. 2007;48:1008–16.
Bennewitz C, Kuwert T, Han J, et al. Computer-aided evaluation of the anatomical accuracy of hybrid SPECT/spiral-CT imaging of lesions localized in the neck and upper abdomen. Nucl Med Commun. 2012;33:1153–9.
Yamamoto Y, Nishiyama Y, Monden T, et al. Clinical usefulness of fusion of 131I SPECT and CT images in patient with differentiated thyroid carcinoma. J Nucl Med. 2003;44:1905–10.
Blum M, Tiu S, Chu M, Goel S, Friedman K. I-131 SPECT/CT elucidates cryptic findings on planar whole-body scans and can reduce needless therapy with iodine-131 in post-thyroidectomy thyroid cancer patients. Thyroid. 2011;21:1235–47.
Avram AM, Fig LM, Frey KA, Gross MD, Wong KK. Preablation 131-I scans with SPECT/CT in postoperative thyroid cancer patients: what is the impact on staging? J Clin Endocrinol Metab. 2013;98:1163–71.
Grewal RK, Tuttle RM, Fox J, et al. The effect of post-therapy 131I SPECT/CT on risk classification and management of patients with differentiated thyroid cancer. J Nucl Med. 2010;51:1361–7.
Ciappuccini R, Heutte N, Trzepla G, et al. Postablation 131I scintigraphy with neck and thorax SPECT/CT and stimulated serum thyroglobulin level predict the outcome of patients with differentiated thyroid cancer. Eur J Endocrinol. 2011;164:961–9.
Wang H, Fu HL, Li JN, et al. The role of single-photon emission computed tomography/computed tomography for precise localization of metastases in patients with differentiated thyroid cancer. Clin Imaging. 2009;33:49–54.
Qiu ZL, Xu YH, Song HJ, et al. Localization and identification of parapharyngeal metastases from differentiated thyroid carcinoma by 131I-SPECT/CT. Head Neck. 2011;33:171–7.
Maruoka Y, Abe K, Baba S, Isoda T, Sawamoto H, Tanabe Y, Sasaki M, Honda H. Incremental diagnostic value of SPECT/CT with 131I scintigraphy after radioiodine therapy in patients with well-differentiated thyroid carcinoma. Radiology. 2012;265:902–9.
Schmidt D, Linke R, Uder M. Five months follow-up of patients with and without iodine-positive lymph node metastases of thyroid carcinoma as disclosed by 131I-SPECT/CT at the first radioablation. Eur J Nucl Med Mol Imaging. 2010;37:699–705.
Barwick T, Murray I, Megadmi H, et al. SPECT/CT using 123I in patients with differentiated thyroid cancer: additional value over whole body planar imaging and SPECT. Eur J Endocrinol. 2010;162:1131–9.
Geerlings JAC, van Zuijlen A, Lohmann EM, et al. The value of 131I SPECT in the detection of recurrent differentiated thyroid cancer. Nucl Med Commun. 2010;31:417–22.
Alnafisi NS, Driedger AA, Coates G, et al. FDG PET of recurrent or metastatic 131I-negative papillary thyroid carcinoma. J Nucl Med. 2000;41:1010–5.
Fletcher JW, Djubegocuc, Soares HP, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med. 2008;49:480–508.
Oh JR, Byun BH, Hong SP, et al. Comparison of 131I whole body imaging, 131I-SPECT/CT, and 18F-FDG PET/CT in the detection of metastatic thyroid cancer. Eur J Nucl Med Mol Imaging. 2011;38:1459–68.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media New York
About this chapter
Cite this chapter
Kulkarni, K., Atkins, F.B., Van Nostrand, D. (2016). The Utility of SPECT-CT in Differentiated Thyroid Cancer. In: Wartofsky, L., Van Nostrand, D. (eds) Thyroid Cancer. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-3314-3_14
Download citation
DOI: https://doi.org/10.1007/978-1-4939-3314-3_14
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-3312-9
Online ISBN: 978-1-4939-3314-3
eBook Packages: MedicineMedicine (R0)